Thomas P. Koestler, Ph.D.


Dr. Koestler has served as a member of Melinta’s board of directors since November 2012 and was elected chairman of the board in April 2013. Dr. Koestler has served as an executive director of Vatera Holdings LLC, the manager of Vatera Healthcare Partners LLC, since February 2010. Dr. Koestler is also a member of the boards of directors of Momenta Pharmaceuticals Inc., ImmusanT, Inc. and Arisaph Pharmaceuticals, Inc. From March 2011 to April 2016 Dr. Koestler served as a member of the board of directors of Novo Nordisk A/S. From 2006 to 2009, Dr. Koestler served as executive vice president of Schering Corporation and president of Schering-Plough Research Institute, the pharmaceutical research and development arm of Schering-Plough Corporation, and served as executive vice president, global development, of Schering-Plough Research Institute from 2005 to 2006, and executive vice president of Schering-Plough Research Institute from 2003 to 2005. Before joining Schering-Plough, Dr. Koestler served as senior vice president and head of global regulatory affairs for Pharmacia Corporation from 2001 to 2003. Before that, Dr. Koestler was senior vice president and global head, drug regulatory affairs, compliance assurance, clinical safety and epidemiology for Novartis. Dr. Koestler received his B.S. from Daemen College and his Ph.D. in Medicine and Pathology from SUNY Buffalo, Roswell Park Memorial Institute. We believe that Dr. Koestler’s scientific expertise, his extensive experience in the pharmaceutical industry as a senior executive and his service as a director of other pharmaceutical companies qualify him to serve on our board of directors.

Melinta Therapeutics, Inc. ©2019 ALL RIGHTS RESERVED | Terms of Use